Thanks Farer, I recall seeing that back then, b
Post# of 15624
(Total Views: 368)
Posted On: 08/29/2017 12:40:13 AM
Thanks Farer,
I recall seeing that back then, but now it appears they may be taking a different course. Had the safety trial begun in April, and if enrollment were quick, it would have concluded in July, as they originally stated.
I believe that the idea that they could expand the Phase 1 trial is a strong probability, and with just a slight additional stretch, I can see them testing people who actually had a variety of skin diseases. While I view this as a Phase 2 portion of the trial, I believe it's very possible.
The first time I ever heard of a Phase 1/2 trial was probably at least 20 years ago when IMGN was doing a Phase 1 Trial, and an investor snooping around the clinical trials database found the Phase 1/2 designation with the Phase 2 portion described. Clearly the trial was modified, and it was only after investors found this information and queried the company that they announced that they were in fact in the Phase 2 portion of the trial.
I've heard that companies like to operate a secretly as they can to not let their competitors know what they're doing. Personally I believe in most cases the competition knows all that's happening, they really are only hiding it from investors, which keeps the price down. The good news is that when all the news does come out, the price will be roughly the same as if they released information much earlier.
If the initial safety trial was complete in July, and the expansion Phase started then, if sufficient patients had already been found for the trial, if the patients were to be observed for 60 days, as the healthy patients were, this expansion could be completed in September. I don't know that they'll complete then, but it would seem to be a possibility. That said, I certainly believe we'll see the data this year, and it's very probable it will be before December. This truly could be a great holiday season.
Gary
I recall seeing that back then, but now it appears they may be taking a different course. Had the safety trial begun in April, and if enrollment were quick, it would have concluded in July, as they originally stated.
I believe that the idea that they could expand the Phase 1 trial is a strong probability, and with just a slight additional stretch, I can see them testing people who actually had a variety of skin diseases. While I view this as a Phase 2 portion of the trial, I believe it's very possible.
The first time I ever heard of a Phase 1/2 trial was probably at least 20 years ago when IMGN was doing a Phase 1 Trial, and an investor snooping around the clinical trials database found the Phase 1/2 designation with the Phase 2 portion described. Clearly the trial was modified, and it was only after investors found this information and queried the company that they announced that they were in fact in the Phase 2 portion of the trial.
I've heard that companies like to operate a secretly as they can to not let their competitors know what they're doing. Personally I believe in most cases the competition knows all that's happening, they really are only hiding it from investors, which keeps the price down. The good news is that when all the news does come out, the price will be roughly the same as if they released information much earlier.
If the initial safety trial was complete in July, and the expansion Phase started then, if sufficient patients had already been found for the trial, if the patients were to be observed for 60 days, as the healthy patients were, this expansion could be completed in September. I don't know that they'll complete then, but it would seem to be a possibility. That said, I certainly believe we'll see the data this year, and it's very probable it will be before December. This truly could be a great holiday season.
Gary
(1)
(0)